We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

First Definitive Data Supporting MMP Inhibitors to Treat Advanced Gastric Cancer

Jul 1, 2000
Volume: 
9
Issue: 
7

BIRMINGHAM, United Kingdom—The first definitive data supporting
the use of matrix metalloproteinase (MMP) inhibitors in treating
gastric cancer were presented by John Fielding at the ASCO annual
meeting.

Dr. Fielding, of Queen Elizabeth Hospital, Birmingham, UK, said the
data showed a significant improvement in survival and in time to
progression for patients with advanced gastric cancer treated with
the MMP inhibitor marimastat, compared to placebo.

The elevated expression of various MMPs found in gastric cancer is
associated with poor prognosis, Dr. Fielding said. The hope was that
inhibiting MMP would slow progression.

“To summarize this study, there was a trend toward survival
benefit, which became statistically significant with follow-up. The
1-year survival was 20% for the marimastat group vs 14% with placebo.
Progression-free survival was improved in the marimastat group.
Patients who had chemotherapy and had just local residual disease
were the particular group who appeared to benefit,” Dr. Fielding said.

First Report of Results

This was the first report of the final results from a multicenter
study comparing marimastat with placebo in patients with advanced
gastric adenocarcinoma. In this study by the Eastern Cooperative
Oncology Group (ECOG 0-1), patients who had received first-line
chemotherapy were eligible if they had responded or had stable disease.

“Recruitment to this trial was fast. We recruited 369 patients
from centers in Europe and the United Kingdom. The first patient was
entered in October 1996, and the trial was completed in October
1998,” Dr. Fielding said.

Inclusion criteria included histologically or cytologically confirmed
gastric adenocarcinoma, with inoperable locally advanced or
metastatic disease. For noncurative surgery, the sites of residual
disease had to be documented.

The protocol called for statistical analysis to take place when 85%
of either group had died or 18 months after the last randomization.
There were to be 180 patients in each group, to provide at least a
90% power.

Survival Differences

The primary endpoint was overall survival. A total of 184 patients
were randomized to placebo and 185 to oral marimastat (10 mg twice
daily for up to 18 months). Sixty-two placebo and 61 marimastat
patients had received prior chemotherapy.

Dr. Fielding reported that median survival was 167 days for
marimastat vs 135 days for placebo, hazard ratio (HR) 1.23, P
= .070 (two-tailed log-rank test). A further 6 months of survival
follow-up showed that the difference between the groups was
maintained (P = .046).

One year survival was 20% for marimastat and 14% for placebo (P
= .12). Progression-free survival was significantly in favor of
marimastat (HR 1.31, P = .015).

Prior Chemotherapy

“The survival difference was much more significant in patients
who had received chemotherapy prior to their marimastat (P =
.045),” Dr. Fielding said. “In the nonchemotherapy
patients, there was no difference between the marimastat group and
the placebo group.”

Patients without distant metastases also had better overall survival
with marimastat (HR 1.74, P = .022). “The numbers are
small in the group with local residual disease who had previous
chemotherapy, but there was a highly significant benefit to receiving
marimastat in this subgroup,” Dr. Fielding said.

No treatment related toxicities were found other than the previously
reported musculoskeletal side effects. “In the marimastat group,
there were many more patients who developed either joint stiffness or
arthritis,” Dr. Fielding said. Two placebo and 18 marimastat
patients stopped treatment because of adverse events.

The investigators concluded that treatment with marimastat resulted
in a significant survival and time-to-disease-progression advantage
for patients with advanced gastric cancer, compared with placebo.

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.